Skip to Main Content

++

SOURCE

++

Source: Deming P. Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=132516044. Accessed April 10, 2017.

++

DEFINITION

++

  • Acute or chronic viral infection of liver.

++

ETIOLOGY

++

  • RNA virus, Flaviviridae family.

++

PATHOPHYSIOLOGY

++

  • Chronic infection develops in majority of cases (75–85%).1

    • Immune response insufficient to eradicate rapidly diversifying virus.

    • Infected hepatocytes undergo apoptosis.2

      • Extent of hepatocyte apoptosis may correlate with extent of disease.

      • Liver damage and hepatocellular carcinoma (HCC) associated with high levels of apoptosis.

      • Viral persistence associated with low levels of apoptosis.

++

EPIDEMIOLOGY

++

  • Most common blood-borne pathogen.

  • Infection transmission routes.

    • Parenterally.

      • Injection-drug use.

      • Other illicit-drug use.

    • Sexual contact.

      • Multiple sexual partners (inefficient)1

      • Coinfection with sexually transmitted infections (STIs)

    • Household exposure, such as sharing personal items (inefficient)1

    • Occupational exposure.

++

PREVENTION AND SCREENING

++

  • Screening recommended in high-risk groups (Table 1)

  • No vaccine available.

++
Table Graphic Jump Location
TABLE 1.Recommendations for Hepatitis C Virus (HCV) Screening
++

RISK FACTORS

++

  • Sexual contact.

  • Injection-drug users.

  • Household contact with HCV-positive person.

  • Blood transfusion or transplant before 1992

  • Clotting factors administered before 1987

  • Chronic hemodialysis.

++

CLINICAL PRESENTATION

++

  • Acute HCV infection.

    • Most patients asymptomatic and undiagnosed.

    • Symptoms occur in one-third of adults 4–12 weeks after infection.1

  • Chronic HCV infection.

    • Defined as persistently detectable HCV RNA for 6 months or more.

    • Develops in majority of patients (75–85%).1

++
SIGNS AND SYMPTOMS
++

  • Acute HCV infection.

    • Fatigue.

    • Anorexia.

    • Weakness.

    • Jaundice.

    • Abdominal pain.

    • Dark urine.

    • Clay-colored stool.

    • Loss of appetite.

    • Nausea and vomiting.

    • Joint pain1

    • Rarely progresses to fulminant hepatitis.

  • Chronic HCV infection.

    • Persistent fatigue most common symptom.

    • Additional symptoms.

      • Right upper quadrant pain.

      • Nausea.

      • Poor appetite.

  • Physical examination.

    • Hepatomegaly.

    • Stigmata of liver disease in advanced disease.

      • Spider nevi.

      • Splenomegaly.

      • Palmar erythema.

      • Testicular atrophy.

      • Caput medusae.

    • Necroinflammatory disease on liver biopsy.

      • Fibrosis.

      • 20–30%3 develop cirrhosis.

      • Patients with cirrhosis have a 2–5% annual risk of developing4:

        • Decompensated cirrhosis.

          ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.